Skip to main content

On Wednesday,

Amylin Pharmaceuticals


removed any surprises about its executive-succession plans, saying Daniel Bradbury has been promoted to president and will become CEO within a year.

Bradbury, 45, will eventually replace Ginger Graham as CEO. Graham, 50, has been president and CEO since September 2003. Prior to joining Amylin, she spent three years at Guidant, which was recently acquired by

Boston Scientific

Scroll to Continue

TheStreet Recommends

(BSX) - Get Boston Scientific Corporation Report


Bradbury joined San Diego-based Amylin in 1994, advancing through several executive posts. He has been chief operating officer since June 2003, and he will retain the title. Amylin's chairman is Joseph Cook Jr.

Amylin specializes in diabetes drugs. Its two marketed products are Symlin and Byetta. The latter drug is sold in collaboration with

Eli Lilly

(LLY) - Get Eli Lilly and Company Report